Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus

American Journal of Gastroenterology

Volumn 101, Issue 7, 2006, Pages 1458-1466

  Vallböhmer, Daniel ^a   DeMeester, Steven R ^b,e   Oh, Daniel S ^a   Banki, Farzaneh ^a   Kuramochi, Hidekazu ^b   Shimizu, Daisuke ^b   Hagen, Jeffrey A ^a   Danenberg, Kathleen D ^c   Danenberg, Peter V ^b   Chandrasoma, Parakrama T ^a   Peters, Jeffrey H ^d   DeMeester, Tom R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics Inc   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL JUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; HEARTBURN; HISTOPATHOLOGY; HUMAN; MALE; MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REFLUX ESOPHAGITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SQUAMOCOLUMNAR JUNCTION; SQUAMOUS EPITHELIUM; STOMACH FUNDOPLICATION;

ADULT; AGED; BIOPSY; CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; ESOPHAGOSCOPY; FEMALE; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33745578572     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00601.x     Document Type: Article

References (26)

1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11.
2. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
3. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7:207-22.
4. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
5. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003;42:457-65.
6. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
7. Hamoui N, Peters JH, Schneider S, et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus, [erratum appears in Arch Surg. 2005 Mar;140(3):249 Note: Valboehmer, Daniel [corrected to Vallbohmer, Daniel]]. Arch Surg 2004;139:712-6; discussion 716-7.
8. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive.
9. Peters JH, DeMeester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: Prospective evaluation of 100 patients with "typical" symptoms. Ann Surg 1998;228:40-50.
10. Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: Molecular analysis of tissue. Science 1997;278:1481-3.
11. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
12. Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:112-27.
13. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31:450-64.
14. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
15. Menges M, Michaeli B, Pueschel W, et al. The influence of the suppression of gastrooesophageal reflux on the gene expression pattern in Barrett's oesophagus. Int J Oncol 2002;20:1323-9.
16. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
17. Bardou M, Barkun AN, Ghosn J, et al. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2004;2:880-7.
18. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.[see comment]. Gastroenterology 2002;122:1101-12.
19. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005;26:565-70.
20. Heath EI, Canto MI, Wu TT, et al. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 2003;16:177-86.
21. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
22. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors.[see comment][summary for patients in Can Fam Physician. 2002 Sep;48:1449-51; PMID: 12371303]. JAMA 2001;286:954-9.
23. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis [see comment]. Lancet 2004;364:2021-9.
24. Solomon SD, Zelenkofske S, McMurray JJV, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both [see comment]. N Engl J Med 2005;352:2581-8.
25. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [see comment]. N Engl J Med 2005;352:1092-102.
26. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: Implications for disease complications. Gut 2002;51:316-22.